Association of estimated liver fibrosis with carotid but not femoral atherosclerotic burden: the ILERVAS cohort
Estimated liver fibrosis, particularly FIB-4, is a valuable marker for identifying carotid subclinical atherosclerosis in populations without known liver disease. These findings highlight the importance of vascular territory-specific evaluations and support their utility in integrated liver and cardiovascular risk assessment strategies.
Authors
- José Manuel Valdivielso (ORCID: https://orcid.org/0000-0003-1343-0184)
- Marı́a M. Malagón (ORCID: https://orcid.org/0000-0002-2419-2727)
- Ana Gordon (ORCID: https://orcid.org/0000-0002-4911-1436)
- Albert Lecube
- Marta Carrasco Hernández (ORCID: https://orcid.org/0000-0002-5901-8390)
- Marcelino Bermúdez-López (ORCID: https://orcid.org/0000-0002-3188-4158)
- Carolina Lopez-Cano
- Kenneth W Cusi
- Elvira Fernández
- Eva Castro
- G.F. Torres
- Rocio Guzman-Ruiz
- Assumpta Caixàs
- Reinald Pamplona
- Josep León-Mengíbar
- Dídac Mauricio
Institutions
- Hebron University (PS)
- Universitat Autònoma de Barcelona (ES)
- Universitat de Lleida (ES)
- University of Florida Health (US)
- Hospital de Sant Pau (ES)
- Hospital Universitari Arnau de Vilanova (ES)
- University of Florida (US)
- Centro de Investigación Biomédica en Red Diabetes y Enfermedades Metabólicas Asociadas (ES)
- Instituto Maimónides de Investigación Biomédica de Córdoba (ES)
- Corporació Sanitària Parc Taulí (ES)
- Hospital de Sabadell (ES)
- Vall d'Hebron Hospital Universitari (ES)
- Instituto de Investigación Biomédica de Lleida (ES)
- Institute of Research and Innovation Parc Tauli (ES)
Publication Details
- Journal
- Frontiers in Endocrinology
- Published
- 2026-01-06
- DOI
- https://doi.org/10.3389/fendo.2025.1651689
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Instituto de Salud Carlos III
- European Regional Development Fund